74-(20)-(20)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name74-(20)-(20)

Drug Alias Nameveltuzumab-Fab-milatuzumab (Immunomedics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate

Mechanisms of ActionHLA-DR antigens-associated invariant chain inhibitorsB-lymphocyte antigen CD20 inhibitors

TargetsHLA-DR antigens-associated invariant chainB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A